Monte Rosa Therapeutic (GLUE) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, to be held virtually for shareholders of record as of April 16, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request by June 1, 2026.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class II director nominees to serve until the 2029 annual meeting or until successors are elected.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.

• Additional business may be transacted if properly brought before the meeting or any adjournment.

Board of directors and corporate governance

• Director nominees for election are Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.